Boehringer Buys Antibody-Drug Conjugates Biotech NBE For €1.18bn
Second Acquisition In ROR1 Space In A Month
Following in the wake of Merck & Co's acquisition of VelosBio, the German major is spending big to get hold of the Swiss oncology biotech NBE-Therapeutics which is also targeting the ROR1 protein.
You may also be interested in...
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Plus deals involving Lilly/Daiichi Sankyo, Humianigen/KPM Tech, Telix/China Grand, Appili/Fujifilm, BioInvent/CASI, Osotec/Adel, Neumentum/Nuance, Takeda/HemoShear and Quantum Genomics/Qilu.
By buying AMAL, Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with the biotech’s KISIMA immunization platform, the German pharma’s head of cancer immunology business development tells Scrip.